MDT-AP-3307
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 6.2
- sex
- M
- new_clusters
- C6
- umap1_2d
- 2.577675528
- umap2_2d
- 6.176746744
- umap1_3d
- 1.596690298
- umap2_3d
- -1.262848092
- umap3_3d
- -4.781756923
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.580
- G2M_CHECKPOINT+0.550
- MITOTIC_SPINDLE+0.450
- PROTEIN_SECRETION+0.400
- MYC_TARGETS_V1+0.310
- DNA_REPAIR+0.210
- PI3K_AKT_MTOR_SIGNALING+0.210
- TGF_BETA_SIGNALING+0.190
- WNT_BETA_CATENIN_SIGNALING+0.180
- UNFOLDED_PROTEIN_RESPONSE+0.150
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.430
- ALLOGRAFT_REJECTION-0.390
- COAGULATION-0.390
- INTERFERON_ALPHA_RESPONSE-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- KRAS_SIGNALING_UP-0.350
- KRAS_SIGNALING_DN-0.340
- IL6_JAK_STAT3_SIGNALING-0.330
- TNFA_SIGNALING_VIA_NFKB-0.320
- HYPOXIA-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_4CP4T22V | Med | Medulloblastoma | 0.939 |
| 2 | MDT-AP-3021 | Med | Medulloblastoma | 0.912 |
| 3 | MDT-AP-3402 | Med | Medulloblastoma | 0.905 |
| 4 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.904 |
| 5 | BS_GNV89A5P | Med | Medulloblastoma | 0.903 |
| 6 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.898 |
| 7 | BS_TV5B86ZD | Embryonal tumors | — | 0.892 |
| 8 | R361 | — | — | 0.891 |
| 9 | MDT-AP-3288 | Med | Medulloblastoma | 0.888 |
| 10 | TCGA-GC-A4ZW-01A-11R-A26T-07 | — | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.070 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.010 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.010 | Inavolisib | — uncovered |